Advances in Transfusion Safety

  • Lorna M. Williamson
  • Jean-Pierre Allain


Although transfusion is now extremely safe, the tools of molecular biology are continually being harnessed to improve diagnosis and therapy. Viral genome testing has been introduced in the developed world for HIV and HCV, to detect donors in the infectious “window period” before sero-conversion. Pathogen inactivated fresh frozen plasma and platelets are already available, but alloimmunization has halted trials of pathogen-inactivated red cells. Development of synthetic oxygen carriers has included perflurocarbons, and crosslinked, polymerized or mutated human or bovine hemoglobin, either free or encapsulated. No perfect replacement for the human red cell is yet on the horizon.

Key Words

Bacterial transmission blood substitutes perfluorocarbons hemoglobin solutions nucleic acid viral testing pathogen inactivation transfusion safety transfusion-transmitted parasites transfusion-transmitted viruses 

Selected References

  1. Allain JP. Genomic screening for blood-borne viruses in transfusion settings. Clin Lab Haematol 2000; 22(1):1–10.PubMedCrossRefGoogle Scholar
  2. Allain JP, Seghatchian J. Current strategies on pathogen removal/inactivation: an overview. Transfus Apheresis Sci 2001; 25(3):195–197.CrossRefGoogle Scholar
  3. Allain JP, Thomas I, Sauleda S. Nucleic acid testing for emerging viral infections. Transfus Med 2002; 12(4):275–283.PubMedCrossRefGoogle Scholar
  4. Blajchman MA. Incidence and significance of the bacterial contamination of blood components. Dev Biol (Basel) 2002; 108:59–67.Google Scholar
  5. Centers for Disease Control and Prevention (CDC). Detection of West Nile virus in blood donations-United States, 2003. MMWR 2003; 52(38): 769–773.Google Scholar
  6. Looker D, Abbott-Brown D, Cozart P, et al. A human recombinant hemoglobin designed for use as a blood substitute. Nature 1992; 356:258–260.PubMedCrossRefGoogle Scholar
  7. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004; 104(5):1534–1541.PubMedCrossRefGoogle Scholar
  8. Mullon J, Giacoppe G, Clagett C, MacCune D, Dillard T. Transfusions of polymerised bovine hemoglobin in a patient with severe autoimmune hemolytic anaemia. N Engl J Med 2000; 342(22): 1638–1643.PubMedCrossRefGoogle Scholar
  9. Nagababu E, Ramasamy S, Abernethy DR, Rifkind JM. Active nitric oxide produced in the red cell under hypoxic conditions by deoxyhemoglobinmediated nitrite reduction.J Biol Chem 2003; 278(47):46,349–46,356.PubMedCrossRefGoogle Scholar
  10. Pillonel J, Laperche S. Groupe “Agents Transmissibles par Transfusion” de la Societe francaise de transfusion sanguine; etablissement francais du sang; Centre de transfusion sanguine des armees. [Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing)]. Transfus Clin Biol 2004; 11(2):81–86.Google Scholar
  11. Stramer SL. NAT update: where are we today? Dev Biol (Basel) 2002; 108:41–56.Google Scholar
  12. Vandegriff KD, Malavalli A, Wooldridge J, Lohman J, Winslow RM. MP4, a new nonvasoactive PEG-Hb conjugate. Transfusion 2003; 43(4):509–516.PubMedCrossRefGoogle Scholar
  13. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inacti-vation treatment: The EuroSPRITE trial. Blood 2003; 101(6):2426–2433.PubMedCrossRefGoogle Scholar
  14. Winslow RM. Blood substitutes: refocusing an elusive goal. Br J Haematol 2000; 111:387–396.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2006

Authors and Affiliations

  • Lorna M. Williamson
    • 1
  • Jean-Pierre Allain
    • 2
  1. 1.FRCPath, Department of HaematologyUniversity of Cambridge/ National Blood ServiceCambridgeUK
  2. 2.Department of HaematologyUniversity of CambridgeCambridgeUK

Personalised recommendations